Blueprint Medicines Corp

Blueprint Medicines — Investor Day (November 2022)

113 slides from Blueprint Medicines's investor day presentation, Nov 1, 2022

  1. Slide 1: ™ oration

    Slide 1: ™ oration

    ™ © 2022 Blueprint Medicines Corporation

  2. Slide 2: Jim Baker, SVP, Corporate Affairs

    Slide 2: Jim Baker, SVP, Corporate Affairs

    JIM BAKER SVP, Corporate Affairs

  3. Slide 3: Our speakers today

    Slide 3: Our speakers today

    INVESTOR DAY 2022 Not for promotional use Our speakers today 3 KATE HAVILAND Chief Executive Officer CHRISTY ROSSI Chief Operating Officer PHILINA LEE, PHD Chief Commercial Officer BECKER HEWES, MD Chief Medical Officer FOUAD NAMOUNI, MD President, R&D PERCY CARTER, PHD Chief Scientific Officer

  4. Slide 4: Agenda

    Slide 4: Agenda

    INVESTOR DAY 2022 Not for promotional use SM, systemic mastocytosis. 4 Agenda Our blueprint to achieve precision at scale Kate Haviland, Chief Executive Officer Delivering the first precision therapy for SM Philina Lee, PhD, Chief Commercial Officer Clinical perspectives on Non-Advanced SM Becker He

  5. Slide 5: Forward-looking statements

    Slide 5: Forward-looking statements

    INVESTOR DAY 2022 Not for promotional use 5 Forward-looking statements Thispresentationcontainsforward-lookingstatementswithinthemeaningofthePrivateSecuritiesLitigationReformActof1995,asamended,including,withoutlimitation,statementsregardingplans, strategies,timelinesandexpectationsforinteractionswi

  6. Slide 6: Our blueprint to achieve precision at scale

    Slide 6: Our blueprint to achieve precision at scale

    INVESTOR DAY 2022 Not for promotional use Our blueprint to achieve precision at scale Chief Executive Officer KATE HAVILAND

  7. Slide 7: Our mission

    Slide 7: Our mission

    INVESTOR DAY 2022 Not for promotional use OUR MISSION Make real the promise of precision therapy to extend and improve life for as many people as possible Not for promotional use Suki, patient with non-advanced systemic mastocytosis

  8. Slide 8: Blueprint's proven track record of success

    Slide 8: Blueprint's proven track record of success

    INVESTOR DAY 2022 Not for promotional use Blueprint’s proven track record of success FDA, U.S. Food and Drug Administration; IND, investigational new drug application; POC, proof-of-concept. development candidates nominated breakthrough therapy designations success rate from IND to clinical POC 14 8

  9. Slide 9: Our evolution to a commercial stage company

    Slide 9: Our evolution to a commercial stage company

    INVESTOR DAY 2022 Not for promotional use 9 Our evolution to a commercial stage company Compelling peak revenue and high margin opportunities leveraging operational efficiencies People, tools and capabilities to capture the compelling growth opportunities Sustainable disease leadership in Systemic M

  10. Slide 10: Our commercial portfolio creates value certainty and opportunity for near-term growth

    Slide 10: Our commercial portfolio creates value certainty and opportunity for near-term growth

    INVESTOR DAY 2022 Not for promotional use Our commercial portfolio creates value certainty and opportunity for near-term growth 10 AREA PDGFRA GIST RET-altered cancers Advanced SM Non-Advanced SM GLOBAL TAMs PRODUCTS Anticipated Approval Mid-2023 ~12,000 patients 2 marketed products GIST, gastrointe

  11. Slide 11: Patient impact and growth driven by Precision at Scale

    Slide 11: Patient impact and growth driven by Precision at Scale

    INVESTOR DAY 2022 Not for promotional use Patient impact and growth driven by Precision at Scale 11 LUNG CANCER PORTFOLIO BLU-222 AREA PDGFRA GIST RET-altered cancers Advanced SM Non-Advanced SM* EGFRm NSCLC* CDK2 vulnerable breast & other cancers* GLOBAL TAMs PRODUCTS ~250,000+ patients 4+ marketed

  12. Slide 12: "2027 Blueprint" strategy - double our impact, in half the time

    Slide 12: "2027 Blueprint" strategy - double our impact, in half the time

    INVESTOR DAY 2022 Not for promotional use 12 “2027 Blueprint” strategy -double our impact, in half the time Approved medicines Disease leadership areas Late-stage clinical programs Research platforms Cumulative development candidates 2011-2022 2 1 2 1 14 Planned 2022-2027 4+ 3+ 4+ 2 25+ 2027

  13. Slide 13: Key questions to be answered today

    Slide 13: Key questions to be answered today

    INVESTOR DAY 2022 Not for promotional use Key questions to be answered today 13 What is the opportunity in Non-Advanced SM and how does our Advanced SM experience inform our view? EXPANDING PATIENT IMPACT SOLVING MAJOR MEDICAL PROBLEMS SCALING INNOVATION Do we have a winning approach to improve outc

  14. Slide 14: Precision at Scale: Bringing AYVAKIT to patients across the spectrum of SM

    Slide 14: Precision at Scale: Bringing AYVAKIT to patients across the spectrum of SM

    INVESTOR DAY 2022 Not for promotional use Precision at Scale: Bringing AYVAKIT to patients across the spectrum of systemic mastocytosis 14 What is the opportunity in Non-Advanced SM and how does our Advanced SM experience inform our view? EXPANDING PATIENT IMPACT 1 2 3 Growing the number of Advanced

  15. Slide 15: Precision at Scale: Delivering improved outcomes for people with EGFR-mutant NSCLC

    Slide 15: Precision at Scale: Delivering improved outcomes for people with EGFR-mutant NSCLC

    INVESTOR DAY 2022 Not for promotional use Precision at Scale: Delivering improved outcomes for people withEGFR-mutant NSCLC 15 SOLVING MAJOR MEDICAL PROBLEMS Do we have a winning approach to improve outcomes for patients with EGFR-mutant NSCLC? 1 2 3 4 BLU-945 monotherapy was clinically active and s

  16. Slide 16: Precision at Scale: Driving innovation for long-term growth

    Slide 16: Precision at Scale: Driving innovation for long-term growth

    INVESTOR DAY 2022 Not for promotional use Precision at Scale: Driving innovation for long-term growth 16 How will we leverage our expertise and infrastructure to drive continued innovation and long-term growth? SCALING INNOVATION 1 2 3 Creating synergies between our robust discovery, clinical and co

  17. Slide 17: Delivering the first precision therapy for systemic mastocytosis

    Slide 17: Delivering the first precision therapy for systemic mastocytosis

    INVESTOR DAY 2022 Not for promotional use Delivering the first precision therapy for systemic mastocytosis Chief Commercial Officer PHILINA LEE, PHD

  18. Slide 18: Our mission

    Slide 18: Our mission

    INVESTOR DAY 2022 Not for promotional use OUR MISSION Make real the promise of precision therapy to extend and improve life for as many people as possible Not for promotional use Melanie, patient with non-advanced systemic mastocytosis

  19. Slide 19: AYVAKIT is the first precision therapy to target the underlying cause of SM

    Slide 19: AYVAKIT is the first precision therapy to target the underlying cause of SM

    INVESTOR DAY 2022 Not for promotional use 19 AYVAKIT is the first precision therapy to target the underlying cause of SM Reduced mast cell burden Improved disease symptoms Improved quality of life Deep and durable clinical responses Positive benefit-risk profile COMPELLING PROFILE DEMONSTRATED ACROS

  20. Slide 20: We are well positioned to deliver on the promise of AYVAKIT in SM

    Slide 20: We are well positioned to deliver on the promise of AYVAKIT in SM

    INVESTOR DAY 2022 Not for promotional use 20 We are well positioned to deliver on the promise of AYVAKIT in SM AYVAKIT has the potential to benefit patients across the spectrum of SM • This represents a >$1B opportunity We have established AYVAKIT as the standard of care for patients treated for Adv

  21. Slide 21: Systemic mastocytosis represents a blockbuster opportunity

    Slide 21: Systemic mastocytosis represents a blockbuster opportunity

    INVESTOR DAY 2022 Not for promotional use Systemic mastocytosisrepresents a blockbuster opportunity 21 ~550 patients ~2,100 patients ~7,500 patients 1 Advanced SM treated 2 Advanced SM untreated 3 Moderate-to-severe non-advanced SM diagnosed & treated 4 Additional opportunity SM PATIENTS IN THE U.S.

  22. Slide 22: Systemic mastocytosis is a spectrum of disease

    Slide 22: Systemic mastocytosis is a spectrum of disease

    INVESTOR DAY 2022 Not for promotional use Systemic mastocytosisis a spectrum of disease AHN, associated hematologic neoplasm. 22 ADVSM(5-10%) ADVSM(5-10%) NON-ADVSM(90-95%) NON-ADVSM(90-95%) •Mast cell proliferationleads to organ damage and shortened overall survival •Managed primarily by hematologi

  23. Slide 23: AYVAKIT has become the standard of care in treated AdvSM in the U.S.

    Slide 23: AYVAKIT has become the standard of care in treated AdvSM in the U.S.

    INVESTOR DAY 2022 Not for promotional use AYVAKIT has become the standard of care in treated AdvSMin the U.S. 23 ~550 patients ~2,100 patients 1 Advanced SM treated 2 Advanced SM untreated 3 Moderate-to-severe non-advanced SM diagnosed & treated 4 Additional opportunity GROWTH OPPORTUNITY Continue t

  24. Slide 24: Growth in AYVAKIT revenue one year into the Advanced SM launch

    Slide 24: Growth in AYVAKIT revenue one year into the Advanced SM launch

    INVESTOR DAY 2022 Not for promotional use 24 Growth in AYVAKIT revenue one year into the Advanced SM launch •AVYAKIT is the standard of care in the U.S. ‒~60% share of treated patients in Q3 ‒~75% of new patient starts / switches ‒Number of patients on therapy continues to grow •Increasing HCP exper

  25. Slide 25: Trending to double AYVAKIT net product revenues compared to last year

    Slide 25: Trending to double AYVAKIT net product revenues compared to last year

    INVESTOR DAY 2022 Not for promotional use 25 Trending to double AYVAKIT net product revenues compared to last year •Updating AYVAKIT net product revenue guidance for full-year 2022 to $108M -$111M, based on: •Continued expected growth of treated patients at a slower pace, driven by expansion ofSM-AH

  26. Slide 26: We are taking action to drive change in AdvSM clinical practice

    Slide 26: We are taking action to drive change in AdvSM clinical practice

    INVESTOR DAY 2022 Not for promotional use 26 We are taking action to drive change in AdvSMclinical practice HCP education , including peer-to-peer, on SM-AHN and urgency to treat Real-time data alerts to field, enhanced by machine learning, to flag patients most likely to start therapy Additional da

  27. Slide 27: Key initiatives to grow the treated AdvSM patient population

    Slide 27: Key initiatives to grow the treated AdvSM patient population

    INVESTOR DAY 2022 Not for promotional use A 20% subset of SM patients identified though AI / machine learning approaches generates ~80% of new SM-directed TKI starts Patient-level data alerts enable highly targeted HCP engagement by field teams = SM patient initiating a TKI or cytoreductive therapy

  28. Slide 28: Non-advanced SM is a significant opportunity with high growth potential

    Slide 28: Non-advanced SM is a significant opportunity with high growth potential

    INVESTOR DAY 2022 Not for promotional use Non-advanced SM is a significant opportunity with high growth potential 28 ~550 patients 1 Advanced SM treated 2 Advanced SM untreated 4 Additional opportunity GROWTH OPPORTUNITY ~7,500 patients with moderate-to-severe Non-AdvSMalready diagnosed and treated

  29. Slide 29: Our U.S. launch strategy focuses on addressing the needs of ~7,500 patients

    Slide 29: Our U.S. launch strategy focuses on addressing the needs of ~7,500 patients

    INVESTOR DAY 2022 Not for promotional use GROWTH OPPORTUNITY EARLIEST ADOPTION Our U.S. launch strategy focuses on addressing the needs of ~7,500 patients U.S. claims data analyses on file. Rx, prescription. 29 ~2,500 severe ~5,000 moderate ~7,500 patients diagnosed with moderate-to-severe Non-AdvSM

  30. Slide 30: Claims data illustrate disease burden and informs field targeting

    Slide 30: Claims data illustrate disease burden and informs field targeting

    INVESTOR DAY 2022 Not for promotional use 30 Claims data illustrate disease burden and informs field targeting 1. Claims algorithm considers number & type of SM diagnosis codes, comorbidities including associated hematologic neoplasms (AHNs) and evidence of organ damage (e.g., splenomegaly, hepatome

  31. Slide 31: Launch strategy to drive continued growth in Non-Advanced SM

    Slide 31: Launch strategy to drive continued growth in Non-Advanced SM

    INVESTOR DAY 2022 Not for promotional use Engage top treaters to raise awareness of SM and need for treatment Educate and empower patients to seek support Launch strategy to drive continued growth in Non-Advanced SM 31 PREPARE LAUNCH ACCELERATE GROW Activate HCPs managing large numbers of patients U

  32. Slide 32: Analytics based on provider segmentation enables efficient, targeted outreach

    Slide 32: Analytics based on provider segmentation enables efficient, targeted outreach

    INVESTOR DAY 2022 Not for promotional use U.S. claims data on file. AI, allergist immunologist; derm, dermatologist; heme/onc, hematologist oncologist; GI, gastroenterologist. 32 Analytics based on provider segmentation enables efficient, targeted outreach Top 350+ HCPs see ~1.5K patients +3K HCPs s

  33. Slide 33: Favorable access to AYVAKIT today provides a strong foundation

    Slide 33: Favorable access to AYVAKIT today provides a strong foundation

    INVESTOR DAY 2022 Not for promotional use Favorable access to AYVAKIT today provides a strong foundation DOSES AVAILABLE TODAY100% PAYER COVERAGERAPID TIME TO FILL All doses approved for AdvSM and GIST, including the 25mg dose, are available and covered by payers 100% payer coverage for all AYVAKIT

  34. Slide 34: Patient support streamlines the access process for patients

    Slide 34: Patient support streamlines the access process for patients

    INVESTOR DAY 2022 Not for promotional use 34 Patient support streamlines the access process for patients SUPPORT OFFERED 1 Minimizes out-of- pocket cost burden for patients 2 Streamlines the access process for patients 3 Provides ongoing information and support to enable adherence PATIENT SUPPORT MO

  35. Slide 35: An educated patient can be a catalyst for disease treatment

    Slide 35: An educated patient can be a catalyst for disease treatment

    INVESTOR DAY 2022 Not for promotional use An educated patient can be a catalyst for disease treatment 35 WEBSITE SOCIAL It’s SM thingpatient and caregiver education campaign First launched in Q1 2022 ~7K patients and caregivers have opted in for routine engagement ~1.3K downloads of a doctor discuss

  36. Slide 36: Breadth of opportunity to drive long-term AYVAKIT growth

    Slide 36: Breadth of opportunity to drive long-term AYVAKIT growth

    INVESTOR DAY 2022 Not for promotional use Breadth of opportunity to drive long-term AYVAKIT growth 36 1 Advanced SM treated 2 Advanced SM untreated 3 Moderate-to-severe non-advanced SM diagnosed and treated 4 Additional opportunity ~6,000 other diagnosed non-advancedSM ~16,000 undiagnosed SM (not vi

  37. Slide 37: Our efforts with the SM community have grown the number of diagnosed patients

    Slide 37: Our efforts with the SM community have grown the number of diagnosed patients

    INVESTOR DAY 2022 Not for promotional use U.S. claims data analyses on file. 37 Our efforts with the SM community have grown the number of diagnosed patients Q2 Q1 2019 Q2Q4Q1 2020 Q1 2022 Q2Q3Q3 Q4Q1 2021 Q4Q2 Q3 Jan’20: AYVAKIT approved for PDGFRA GIST PREVALENT SM PATIENTS OBSERVED IN US CLAIMS D

  38. Slide 38: We are well positioned to deliver on the promise of AYVAKIT in SM

    Slide 38: We are well positioned to deliver on the promise of AYVAKIT in SM

    INVESTOR DAY 2022 Not for promotional use 38 We are well positioned to deliver on the promise of AYVAKIT in SM AYVAKIT has the potential to benefit patients across the spectrum of SM • This represents a >$1B opportunity We have established AYVAKIT as the standard of care for patients treated for Adv

  39. Slide 39: Clinical perspectives on non-advanced SM

    Slide 39: Clinical perspectives on non-advanced SM

    INVESTOR DAY 2022 Not for promotional use Clinical perspectives on non-advanced SM Chief Medical Officer BECKER HEWES, MD

  40. Slide 40: Uncontrolled mast cell proliferation and activation in Non-Advanced SM causes severe symptoms

    Slide 40: Uncontrolled mast cell proliferation and activation in Non-Advanced SM causes severe symptoms

    INVESTOR DAY 2022 Not for promotional use Uncontrolled mast cell proliferation and activation in Non-Advanced SM causes severe and unpredictable symptoms across multiple organ systems 1-3 40 Syncope, dizziness, palpitations, Hypotensive anaphylaxis Diarrhea, nausea/vomiting, painBone/muscle pain, os

  41. Slide 41: The first study to show disease modification and benefit in indolent SM

    Slide 41: The first study to show disease modification and benefit in indolent SM

    INVESTOR DAY 2022 Not for promotional use 41 THE FIRST STUDY TO SHOW DISEASE MODIFICATION AND BENEFIT IN INDOLENT SYSTEMIC MASTOCYTOSIS

  42. Slide 42: PIONEER: Largest clinical trial in Non-Advanced SM

    Slide 42: PIONEER: Largest clinical trial in Non-Advanced SM

    INVESTOR DAY 2022 Not for promotional use PIONEER: Largest clinical trial in Non-Advanced SM Data cutoff as of June 23, 2022. QD, once daily; BSC, best supportive care; QD, once daily; SD, standard deviation. 42 PART 1: DOSE-FINDING AYVAKIT 25 mg QD + BSC AYVAKIT 50 mg QD + BSC AYVAKIT 100 mg QD + B

  43. Slide 43: AYVAKIT demonstrated highly significant and clinically meaningful impact

    Slide 43: AYVAKIT demonstrated highly significant and clinically meaningful impact

    INVESTOR DAY 2022 Not for promotional use AYVAKIT demonstrated highly significant and clinically meaningful impact Data cutoff as of June 23, 2022. 1. One-sided p-value < 0.025 indicates statistical significance. 2. For secondary endpoints, reductions in TSS and objective measures of mast cell burde

  44. Slide 44: AYVAKIT decreased patient-reported symptoms and objective measures of disease burden

    Slide 44: AYVAKIT decreased patient-reported symptoms and objective measures of disease burden

    INVESTOR DAY 2022 Not for promotional use Data cutoff as of June 23, 2022. CI, confidence interval; SD, standard deviation AYVAKIT decreased patient-reported symptoms and objective measures of disease burden PART 2: PRIMARY ENDPOINT Mean change in Total Symptom Score (TSS) [95% CI] AYVAKIT -20.2 [-2

  45. Slide 45: AYVAKIT was well-tolerated with a safety profile favorable to control

    Slide 45: AYVAKIT was well-tolerated with a safety profile favorable to control

    INVESTOR DAY 2022 Not for promotional use AYVAKIT was well-tolerated with a safety profile favorable to control Data cutoff as of June 23, 2022. 1. Cognitive effect AEs refer to 17 pooled terms identified across AYVAKIT clinical studies.AE, adverse event; ICB, intracranial bleed; SAE, serious advers

  46. Slide 46: Maximum symptom improvement seen with 25 mg irrespective of tryptase reduction

    Slide 46: Maximum symptom improvement seen with 25 mg irrespective of tryptase reduction

    INVESTOR DAY 2022 Not for promotional use * >50 ng/ml at baseline. TSS, total symptom score. 46 Maximum symptom improvement seen with 25 mg irrespective of tryptase reduction Part 1 Part 2 ****** -100% -50% 0% 50% 100% 25mg (n=10) 50 mg (n=10) 100 mg (n=10) * no data available Placebo (n=9) % CHANGE

  47. Slide 47: Non-Advanced SM patients had poor QoL and improved on AYVAKIT

    Slide 47: Non-Advanced SM patients had poor QoL and improved on AYVAKIT

    INVESTOR DAY 2022 Not for promotional use Health State Mobility Self- Care Usual Activities Pain / Discomfort Anxiety / Depression NON-ADVANCED SM PATIENT QOL IS LOWER THAN SOME TERMINAL DISEASES AYVAKIT LED TO CLINICALLY MEANINGFUL INCREASES IN QOL AT 24 WEEKS QOL, Quality of Life 1. Average EQ-5D

  48. Slide 48: AYVAKIT showed reduction in polypharmacy: illustrative example oral cromolyn

    Slide 48: AYVAKIT showed reduction in polypharmacy: illustrative example oral cromolyn

    INVESTOR DAY 2022 Not for promotional use AYVAKIT showed reduction in polypharmacy: illustrative example oral cromolyn Anti-IgE, anti-immunoglobulin E; NSAIDS, non-steroidal anti-inflammatory drugs. 48 MEDICATION CLASSES MULTIPLE SYMPTOMS H1 inhibitors H2 inhibitors Leukotriene inhibitors Systemic s

  49. Slide 49: Case presentations & panel discussion

    Slide 49: Case presentations & panel discussion

    CASE PRESENTATIONS & PANEL DISCUSSION Assistant Professor of Medicine Hematology Oncology University of Alabama School of Medicine Birmingham, Alabama Pioneer Investigator PANKITVACHHANI, MD Professor of Medicine Division of Allergy and Immunology Washington University St. Louis, Missouri H. JAMES W

  50. Slide 50: Case - Prof. Siebenhaar: baseline symptomology

    Slide 50: Case - Prof. Siebenhaar: baseline symptomology

    INVESTOR DAY 2022 Not for promotional use BASELINE SYMPTOMOLOGY 50 Case 1 –Prof. Siebenhaar GI : recurrent, unpredictable diarrhea Neuro: Brain fog, dizziness, headache Skin : lesions < 60%; triggered by exercise, shower, hot bath Skeletal: Bone pain 34-year-old man •Allergic rhinitis, asthma in 199

  51. Slide 51: Case 1 - Symptom & QoL improvement after 6 months AYVAKIT treatment

    Slide 51: Case 1 - Symptom & QoL improvement after 6 months AYVAKIT treatment

    INVESTOR DAY 2022 Not for promotional use 1. Jiang R, et al., Qual Life Research. 2021;30. ISM, indolent SM; MC-QOL, mastocytosisquality of life questionnaire. 51 Case 1 –Symptom & QoL improvement after 6 months AYVAKIT treatment Emotions Skin Social Life/ Functioning Symptoms Total Score MC-QOL (lo

  52. Slide 52: Case - Symptoms and overall improvements

    Slide 52: Case - Symptoms and overall improvements

    INVESTOR DAY 2022 Not for promotional use 52 Case 1 –Symptoms and overall improvements SKIN IMPROVEMENTS Before After • Patient reports “life-changing” improvement , including continued improvement in QoL – Ability to be more productive at work •No new symptoms, and reduction in skin and GI symptoms

  53. Slide 53: Case - Dr. Vachhani: baseline symptomology

    Slide 53: Case - Dr. Vachhani: baseline symptomology

    INVESTOR DAY 2022 Not for promotional use BASELINE SYMPTOMOLOGY 53 Case 2 –Dr. Vachhani GI : Chronic diarrhea, pain with food Neuro: Brain fog Skin : Typical SM lesions on trunk and limbs Skeletal: Bone Pain Systemic: Recurrent anaphylaxis, flushing 39-year-old mother of four •First symptoms in 2017

  54. Slide 54: Case - Quality of life improvements

    Slide 54: Case - Quality of life improvements

    INVESTOR DAY 2022 Not for promotional use 1. Jiang R, et al., Qual Life Research. 2021;30 54 Case 2 –Quality of life improvements avapritinib25mg Week 19 Baseline Emotions Skin Social Life/ Functioning Symptoms Total Score +38% U.S. General Population 1 MC-QOL (lower = health improvement) EQ-5D (hig

  55. Slide 55: Dr. Wedner's Practice - Washington University

    Slide 55: Dr. Wedner's Practice - Washington University

    INVESTOR DAY 2022 Not for promotional use Dr. Wedner’sPractice –Washington University Division of Allergy & Immunology Systemic Mastocytosis Practice • Treats multiple disorders including HAE, resistant atopic diseases, & routine allergy disorders • Currently ~50 patients with SM ‒ ~5-10 advanced SM

  56. Slide 56: Case Study #3 - Dr. Wedner

    Slide 56: Case Study #3 - Dr. Wedner

    INVESTOR DAY 2022 Not for promotional use 56 Case Study #3 –Dr. Wedner 41-year-old woman •Referred by local ER for anaphylaxis • GI : Frequent stomach upset • Skin : Years of itching and skin flushing • Systemic: Occasional shortness of breath Polypharmacy Additional History & Testing Presentation •

  57. Slide 57: A new era for patients with Systemic Mastocytosis

    Slide 57: A new era for patients with Systemic Mastocytosis

    INVESTOR DAY 2022 Not for promotional use 57 A new era for patients with Systemic Mastocytosis Non-Advanced SM is a devastating disease without any disease modifying treatment options PIONEER data support AYVAKIT's efficacy as the first disease modifying agent, with safety data at 25 mg highlighting

  58. Slide 58: Clinical panel Q&A

    Slide 58: Clinical panel Q&A

    CLINICAL PANEL Q&A Assistant Professor of Medicine Hematology Oncology University of Alabama School of Medicine Birmingham, Alabama Pioneer Investigator PANKITVACHHANI, MD Professor of Medicine Division of Allergy and Immunology Washington University St. Louis, Missouri H. JAMES WEDNER, MD Assistant

  59. Slide 59: Break

    Slide 59: Break

  60. Slide 60: Expanding patient impact with precision medicine leadership

    Slide 60: Expanding patient impact with precision medicine leadership

    INVESTOR DAY 2022 Not for promotional use Expanding patient impact with precision medicine leadership President, R&D FOUAD NAMOUNI, MD

  61. Slide 61: Our proven research and development engine

    Slide 61: Our proven research and development engine

    INVESTOR DAY 2022 Not for promotional use Our proven research and development engine development candidates nominated breakthrough therapy designations success rate from IND to clinical POC 14 80% 5 years from IND to first approval FDA approved indications approved medicines ~4 25 61

  62. Slide 62: Targeting areas of high medical need and scaled patient impact

    Slide 62: Targeting areas of high medical need and scaled patient impact

    INVESTOR DAY 2022 Not for promotional use wt-KIT, wild-type KIT. 62 Targeting areas of high medical need and scaled patient impact MAST CELL DISEASES LUNG CANCER BREAST CANCER CANCER IMMUNOTHERAPY AYVAKIT: KIT D816V BLU-263: KIT D816V Research: wt-KIT GAVRETO: RET BLU-945: EGFR BLU-701: EGFR BLU-525

  63. Slide 63: We will achieve R&D scale by leveraging our strengths

    Slide 63: We will achieve R&D scale by leveraging our strengths

    INVESTOR DAY 2022 Not for promotional use We will achieve R&D scale by leveraging our strengths 63 LEADING PRECISION MEDICINE RESEARCH PLATFORM ADVANCED TRANSLATIONAL MEDICINE APPROACHES CULTURE OF INNOVATION Scientific rigor and depth Scientific rigor and depth Urgency to help patients Urgency to h

  64. Slide 64: Transforming treatment of EGFRm lung cancer

    Slide 64: Transforming treatment of EGFRm lung cancer

    Transforming treatment of EGFRm lung cancer President, R&D FOUAD NAMOUNI, MD

  65. Slide 65: Our progress in addressing the medical need in EGFRm NSCLC

    Slide 65: Our progress in addressing the medical need in EGFRm NSCLC

    INVESTOR DAY 2022 Not for promotional use 1. American Cancer Society. Key Statistics About Lung Cancer. https://www.cancer.org/cancer/lung-cancer/about/key-statistics .. 2. Approximate patient numbers covering major markets –US, EU4, UK, and Japan. 1. Excludes rare mutations including exon 20 insert

  66. Slide 66: Patients with EGFRm NSCLC have significant medical needs despite standard of care

    Slide 66: Patients with EGFRm NSCLC have significant medical needs despite standard of care

    INVESTOR DAY 2022 Not for promotional use Patients with EGFRm NSCLC have significant medical needs despite standard of care EGFRmNSCLCPROGRESSION ON TARGET EGFR RESISTANCE C797X, L718X, L792X, G796X, etc. OFF TARGET RESISTANCE MET, ALK, RET, KRAS, BRAF, CCNE1, etc. INCOMPLETE DRIVER INHIBITION Poore

  67. Slide 67: Poorer outcomes in EGFR L858R are associated with incomplete EGFR inhibition

    Slide 67: Poorer outcomes in EGFR L858R are associated with incomplete EGFR inhibition

    INVESTOR DAY 2022 Not for promotional use Poorer outcomes in EGFR L858R are associated with incomplete EGFR inhibition 67 21.4 mo ex19del OS ~42 mo PFS 14.4 mo L858R ~31 mo OSIMERTINIBOUTCOMES IN FLAURA 1L NSCLC 1 ex19delL858R osimertinib Complete EGFR inhibition Incomplete EGFR inhibition OSIMERTIN

  68. Slide 68: Our EGFR portfolio strategy is comprehensive and modular

    Slide 68: Our EGFR portfolio strategy is comprehensive and modular

    INVESTOR DAY 2022 Not for promotional use Target coverage based on preclinical data; Ref: Riess2018 J ThoracOncol. 68 Our EGFR portfolio strategy is comprehensive and modular BLU-945 BLU-701/525 BLU-451 •More potent on L858R than ex19del •Covers EGFR T790M and C797S •Potent coverage of L858R and ex1

  69. Slide 69: BLU-945 dose escalation data in late-line patients

    Slide 69: BLU-945 dose escalation data in late-line patients

    INVESTOR DAY 2022 Not for promotional use 69 BLU-945 dose escalation data in late-line patients Updated BLU-945 monotherapy dose escalation data show: – Differentiated safety with limitedwild-type-EGFR-related adverse events that were not dose limiting – Robust target ctDNAresponses leading to tumor

  70. Slide 70: BLU-945 monotherapy dose escalation data support combination development

    Slide 70: BLU-945 monotherapy dose escalation data support combination development

    INVESTOR DAY 2022 Not for promotional use Data cutoff date: September 13, 2022. BID, twice daily; C1D1, cycle 1 day 1; C1D15, cycle 1 day 15; DLT, dose-limited toxicity; LFT, liver function tests. PD, progressive disease; PR, partial response; RP2D, recommended phase 2 dose; SD, stable disease; VAF,

  71. Slide 71: Significant off-target resistance limits opportunity for EGFR targeted therapy in 2L+

    Slide 71: Significant off-target resistance limits opportunity for EGFR targeted therapy in 2L+

    INVESTOR DAY 2022 Not for promotional use Data cutoff date: September 13, 2022. **RB1 and TP53 loss is evidence for likely histological transformation; OffinM. J ThoracOncol, 2019. 71 Significant off-target resistance limits opportunity for EGFR targeted therapy in 2L+ •Significant tumor heterogenei

  72. Slide 72: BLU-945's unique selectivity profile enables a wide therapeutic index

    Slide 72: BLU-945's unique selectivity profile enables a wide therapeutic index

    INVESTOR DAY 2022 Not for promotional use Data on file. IC50, half-maximal inhibitory concentration; WT, wild-type; wtEGFR, wild-type EGFR. 72 BLU-945’s unique selectivity profile enables a wide therapeutic index and more potent inhibition of L858R with or without on-target resistance 0 10 20 30 40

  73. Slide 73: BLU-945 and osimertinib combine to more completely inhibit EGFR and extend survival

    Slide 73: BLU-945 and osimertinib combine to more completely inhibit EGFR and extend survival

    INVESTOR DAY 2022 Not for promotional use Tavera-Mendoza. EORTC-NCI-AACR, 2022. mOS, median overall survival; PDX, patient-derived xenograft model; SEM, standard error of the mean. 73 BLU-945 and osimertinibcombine to more completely inhibit EGFR and extend survival in treatment-naïve L858R preclini

  74. Slide 74: Early SYMPHONY trial data show BLU-945 + osimertinib generally well-tolerated

    Slide 74: Early SYMPHONY trial data show BLU-945 + osimertinib generally well-tolerated

    INVESTOR DAY 2022 Not for promotional use Early SYMPHONY trial dose escalation data show BLU-945 + osimertinib combination has been generally well-tolerated to date Data cutoff date: September 13, 2022. 74 BLU-945 + OSIMERTINIB 80 MG DOSE ESCALATION Patients with EGFRm NSCLC and >1 prior TKI BLU-945

  75. Slide 75: Plan to prioritize BLU-525, with minimal disruption to EGFR portfolio timeline

    Slide 75: Plan to prioritize BLU-525, with minimal disruption to EGFR portfolio timeline

    INVESTOR DAY 2022 Not for promotional use 75 Plan to prioritize BLU-525, with minimal disruption to overall EGFR portfolio timeline Phase 1 HARMONY trial dose escalation update • BLU-701 showed early evidence of activity at low doses • Drug metabolism pathway has limited dose escalation Plan to prio

  76. Slide 76: BLU-451 escalation ongoing with early response in EGFR ex20ins patient

    Slide 76: BLU-451 escalation ongoing with early response in EGFR ex20ins patient

    INVESTOR DAY 2022 Not for promotional use BLU-451 escalation ongoing with early response in EGFR ex20ins patient 76 63 yoF with ex20ins NSCLC Prior therapies: •carbo/pemetrexed/pembro •CLN-081 (dc’dfor toxicity) •BDTX-189 (dc’dfor PD) Phase 1 CONCERTO trial dose escalation update •Currently enrollin

  77. Slide 77: Our EGFR portfolio strategy is comprehensive and modular

    Slide 77: Our EGFR portfolio strategy is comprehensive and modular

    INVESTOR DAY 2022 Not for promotional use 77 Our EGFR portfolio strategy is comprehensive and modular BLU-945 BLU-525 BLU-451 12% 9% 47% 32% ex19del L858R Exon 20 insertions Atypical EGFR G719X, L861Q, etc. + osimertinib 1L NSCLC with EGFR L858R •2L+ exon20 NSCLC •1L exon20 NSCLC + BLU-945 1L NSCLC

  78. Slide 78: Precision at Scale: Delivering improved outcomes for people with EGFR-mutant NSCLC

    Slide 78: Precision at Scale: Delivering improved outcomes for people with EGFR-mutant NSCLC

    INVESTOR DAY 2022 Not for promotional use Precision at Scale: Delivering improved outcomes for people withEGFR-mutant NSCLC 78 SOLVING MAJOR MEDICAL PROBLEMS Do we have a winning approach to improve outcomes for patients with EGFR-mutant NSCLC? 1 2 3 4 BLU-945 monotherapy was clinically active and s

  79. Slide 79: Research innovation at scale

    Slide 79: Research innovation at scale

    INVESTOR DAY 2022 Not for promotional use Research innovation at scale Chief Scientific Officer PERCY CARTER, PHD

  80. Slide 80: Blueprint's Science Leadership Team

    Slide 80: Blueprint's Science Leadership Team

    INVESTOR DAY 2022 Not for promotional use 80 Blueprint’s Science Leadership Team ROB MEISSNER, PHD SVP, Chemical Sciences RACHEL ERLICH, PHD VP, Translational Medicine & Integrated Research TIM LABRANCHE, DVM, PHD VP, Preclinical Safety & Comparative Medicine STEVE MILLER, PHD VP, Precision Open Inn

  81. Slide 81: Research at Blueprint Medicines

    Slide 81: Research at Blueprint Medicines

    INVESTOR DAY 2022 Not for promotional use 81 Research at Blueprint Medicines Blueprint Talent + Integrated Platforms Blueprint Precision Medicine Research Portfolio Blueprint Clinical Portfolio KIT EGFR CDK •Support development and enhancement of three therapeutic areas •Lead the creation of new the

  82. Slide 82: Research at Blueprint Medicines: external partnerships

    Slide 82: Research at Blueprint Medicines: external partnerships

    INVESTOR DAY 2022 Not for promotional use 82 Research at Blueprint Medicines Blueprint Talent + Integrated Platforms Blueprint Precision Medicine Research Portfolio Blueprint Clinical Portfolio KIT EGFR CDK Externally Partnered Programs Bus. Dev. & Research Partnerships Augment our internal efforts

  83. Slide 83: We have a focused approach to portfolio construction

    Slide 83: We have a focused approach to portfolio construction

    INVESTOR DAY 2022 Not for promotional use 83 We have a focused approach to portfolio construction At all stages, early to late, we progress programs that have: Defined Value Inflections Delineated data-driven decision points at all R&D stages Blueprint Edge Benefits from our focused approach to smal

  84. Slide 84: Today's update

    Slide 84: Today's update

    INVESTOR DAY 2022 Not for promotional use 84 Today’s update Blueprint Talent + Integrated Platforms Blueprint Precision Medicine Research Portfolio Blueprint Clinical Portfolio KIT EGFR CDK Wild-type KIT program Immuno-oncology collaboration with Roche EGFR Backup Candidate CDK2 program Targeted Pro

  85. Slide 85: Our EGFR portfolio has potential to address all known driver mutations

    Slide 85: Our EGFR portfolio has potential to address all known driver mutations

    INVESTOR DAY 2022 Not for promotional use Target coverage based on preclinical data; Ref: Riess2018 J ThoracOncol. 85 Our EGFR portfolio has potential to address all known driver mutations and associated resistance mechanisms BLU-945 BLU-525 BLU-451 •More potent on L858R than ex19del •Covers EGFR T7

  86. Slide 86: BLU-525 is an improved brain penetrant, reversible EGFR inhibitor

    Slide 86: BLU-525 is an improved brain penetrant, reversible EGFR inhibitor

    INVESTOR DAY 2022 Not for promotional use BLU-701BLU-525 Potency (IC 50 , nM) [WT-selectivity] Exon19Deletion (enzyme / cell pEGFRPC9) 0.5 [109x] / 1.3 [83x]0.9 [19x] / 1.2 [96x] Exon19Deletion C797S (cell pEGFRBa/F3 Ex19Del/CS) 1.8 [107x]9.5 [12x] L858R (enzyme / cell pEGFRBa/F3 LR) 2.6 [21] / 3.3[

  87. Slide 87: BLU-525 and BLU-945 EGFR mutational coverage

    Slide 87: BLU-525 and BLU-945 EGFR mutational coverage

    INVESTOR DAY 2022 Not for promotional use 87 BLU-525 is an improved brain penetrant, reversible EGFR inhibitor Together, BLU-525 and BLU-945 will cover both common EGFR mutations and associated primary resistance mutations EGFR mutational coverage* GefitinibOsimertinibBLU-525BLU-945 BLU-525 + osimer

  88. Slide 88: Targeting cancer pathways vulnerable to CDK2 inhibition

    Slide 88: Targeting cancer pathways vulnerable to CDK2 inhibition

    INVESTOR DAY 2022 Not for promotional use 88 Targeting cancer pathways vulnerable to CDK2 inhibition Precision Medicine Critical Role in Progression Ovarian Cancer (20%) Endometrial Carcinoma (11%) Lung Adenocarcinoma (5%) Gastric Cancer (11%) Esophageal Cancer (8%) Triple Negative Breast Cancer (11

  89. Slide 89: BLU-222 is a highly potent and selective CDK2 inhibitor

    Slide 89: BLU-222 is a highly potent and selective CDK2 inhibitor

    INVESTOR DAY 2022 Not for promotional use 89 BLU-222 is a highly potent and selective CDK2 inhibitor BLU-222 CELL pRb IC 50 (nM) 4.2 pLamin / pRb (CDK1/2) 84x ENZYME (1mM ATP) CDK2 IC 50 (nM) 2.6 CDK4/2 150x CDK6/2 105x CDK7/2 2,700x CDK9/2 2,300x S(10) 0.045 BLU-222 has excellent potency, CDK-famil

  90. Slide 90: Broad R&D effort to support ongoing development of BLU-222

    Slide 90: Broad R&D effort to support ongoing development of BLU-222

    INVESTOR DAY 2022 Not for promotional use CDK4/6i, CDK4/6 inhibitor. 90 Broad R&D effort to support ongoing development of BLU-222 Multiple dose cohorts* RP2D BLU-222 + ER antagonist (ER+/HER2-breast) BLU-222 + CDK4/6i + ER antagonist (ER+/HER2-breast) BLU-222 Monotherapy (CCNE1+ tumors) PHASE 2 EXP

  91. Slide 91: Scientific leadership in KIT biology

    Slide 91: Scientific leadership in KIT biology

    INVESTOR DAY 2022 Not for promotional use GIST, gastrointestinal stromal tumor; mMCAS, monoclonal mast cell activation syndrome. 91 Scientific leadership in KIT biology KIT BLU-263 IDRX-73 (BLU-654) KIT exon 13 inhibitor for KIT-driven GIST out-licensed to IDRx wt-KIT Research program for inflammato

  92. Slide 92: Expanding our leadership in mast cell-mediated diseases

    Slide 92: Expanding our leadership in mast cell-mediated diseases

    INVESTOR DAY 2022 Not for promotional use *See: J. Fricke, J. et al. Allergy 2020 , 75 , 423; note that point prevalence was estimated based on regional data (Fricke) and current populations **See: P. Kolkhir, et al. Nature Reviews: Disease Primers 2022 , 8 : 61; 92 Expanding our leadership in mast

  93. Slide 93: Aim to discover best-in-class wild-type KIT inhibitors

    Slide 93: Aim to discover best-in-class wild-type KIT inhibitors

    INVESTOR DAY 2022 Not for promotional use 93 Aim to discover best-in-class wild-type KIT inhibitors We have identified multiple examples of compounds meeting our target product profile Advanced candidates have safety and ADME profiles consistent with either single agent or combination therapy Attrib

  94. Slide 94: A strategic collaboration with the potential to transform cancer immunotherapy

    Slide 94: A strategic collaboration with the potential to transform cancer immunotherapy

    INVESTOR DAY 2022 Not for promotional use 94 A strategic collaboration with the potential to transform the field of cancer immunotherapy Robust kinase research platform & development capabilities Cancer immunotherapy expertise, assets and infrastructure EXPLORE COMPELLING TARGETS • Goal: Explore a r

  95. Slide 95: Platform diversification expands our vision and impact

    Slide 95: Platform diversification expands our vision and impact

    INVESTOR DAY 2022 Not for promotional use Degrader figure from Nalawansha& Crews, Cell Chemical Biology 2020 , 27 , 998 –1014. 95 Platform diversification expands our vision and impact KINASE MEDICINE DISCOVERY PLATFORM AGILE DEGRADER DISCOVERY PLATFORM + Internal investment provides flexibility acr

  96. Slide 96: Strategy: Leverage the Blueprint library

    Slide 96: Strategy: Leverage the Blueprint library

    INVESTOR DAY 2022 Not for promotional use 96 Strategy: Leverage the Blueprint library Our initial approach prioritizes heterobifunctional degraders, which can capitalize both on existing proprietary chemical matter and known E3 ligases. BLUEPRINT KINASE INHIBITOR LIBRARY Select potent, selective, an

  97. Slide 97: Portfolio impact: early degrader example

    Slide 97: Portfolio impact: early degrader example

    INVESTOR DAY 2022 Not for promotional use 97 Portfolio impact Early Example: Internal kinase program with family selectivity challenges (oncology) Exploratory work revealed a selectivity divergence in inhibitor vs degrader SAR, and ability to tune selectivity Impact: opportunistic program initiation

  98. Slide 98: Expanding the research platform to increase innovation & productivity

    Slide 98: Expanding the research platform to increase innovation & productivity

    INVESTOR DAY 2022 Not for promotional use 98 Expanding the research platform to increase innovation & productivity KINASE PLATFORM KINASE PLATFORM NEW PLATFORMS INTEGRATED PLATFORM CURRENT CAPABILITIES TARGETED PROTEIN DEGRADATION UNPARALLELED PRODUCTIVITY COMPLEMENTARY & SCALABLE NEW TARGET CLASSES

  99. Slide 99: Pre-clinical portfolio

    Slide 99: Pre-clinical portfolio

    INVESTOR DAY 2022 Not for promotional use 99 Pre-clinical portfolio Hit ID and Hit-to-Lead Lead Optimization PreclinicalDevelopment BLU-525 MAP4K1 I/O Target #2 Collaboration with Undisclosed Undisclosed Wild-type KIT Undisclosed Multiple Inhibitors Precision Oncology Heme & Mast Cells Immuno- Oncol

  100. Slide 100: Precision at Scale: Driving innovation for long-term growth

    Slide 100: Precision at Scale: Driving innovation for long-term growth

    INVESTOR DAY 2022 Not for promotional use Precision at Scale: Driving innovation for long-term growth 100 How will we leverage our expertise and infrastructure to drive continued innovation and long-term growth? SCALING INNOVATION 1 2 3 Creating synergies between our robust discovery, clinical and c

  101. Slide 101: Scaling our leadership in precision medicine

    Slide 101: Scaling our leadership in precision medicine

    INVESTOR DAY 2022 Not for promotional use Scaling our leadership in precision medicine Chief Operating Officer CHRISTY ROSSI

  102. Slide 102: A clear portfolio strategy to achieve our 2027 vision

    Slide 102: A clear portfolio strategy to achieve our 2027 vision

    INVESTOR DAY 2022 Not for promotional use 102 A clear portfolio strategy to achieve our 2027 vision LEAD WITH THE SCIENCE Patient needs Important targets Blueprint edge DIVERSIFY RISK Next-gen strategies Balance risk & return BUILD SCALE Target & disease leadership areas LEVERAGE PARTNERSHIPS Scient

  103. Slide 103: Diversified EGFRm NSCLC portfolio with a compelling risk-return profile

    Slide 103: Diversified EGFRm NSCLC portfolio with a compelling risk-return profile

    INVESTOR DAY 2022 Not for promotional use 103 Diversified EGFRm NSCLC portfolio with a compelling risk-return profile ASSET AND OPPORTUNITY DIVERSITY ENABLES: •Balanced risk profile •Attractive commercial opportunity •Scientific, clinical, and commercial economies of scale TECHNICAL RISK TECHNICAL R

  104. Slide 104: Strategic use of back-up and next-gen programs in high value opportunities

    Slide 104: Strategic use of back-up and next-gen programs in high value opportunities

    INVESTOR DAY 2022 Not for promotional use 104 Strategic use of back-up and next-gen programs in high value opportunities BLU-701 BLU-525 BLU-263 AYVAKIT DEEP BIOLOGICAL INSIGHTS ENABLE NEXT-GENERATION PROGRAMS Goal: expand patient impact, disease area leadership and program lifecycle ROUTINE BACK-UP

  105. Slide 105: We are leaders in systemic mastocytosis

    Slide 105: We are leaders in systemic mastocytosis

    INVESTOR DAY 2022 Not for promotional use We are leaders in systemic mastocytosis 105 ~540 patient years of SM clinical data 3 FDA breakthrough therapy designations 2 FDA and EMA approved indications* On track to submit sNDAto FDA for non-advanced SM by the end of 2022 EMA, European Medicines Author

  106. Slide 106: Deep disease insights drive perspectives on medical needs

    Slide 106: Deep disease insights drive perspectives on medical needs

    INVESTOR DAY 2022 Not for promotional use 106 Deep disease insights drive perspectives on medical needs ADVSM(5-10%) ADVSM(5-10%) NON-ADVSM(90-95%) NON-ADVSM(90-95%) •AVYAKIT is the standard of care •Areas for continued innovation: ‒Long term follow up and OS ‒Combination data SYSTEMIC MASTOCYTOSIS

  107. Slide 107: Business development is a key lever in our portfolio strategy

    Slide 107: Business development is a key lever in our portfolio strategy

    INVESTOR DAY 2022 Not for promotional use Business development is a key lever in our portfolio strategy 107 Strategic Partnerships Strategic Partnerships Geographic Expansion Geographic Expansion Buy-Side Transactions Buy-Side Transactions Program Partnerships Program Partnerships FOP, fibrodysplasi

  108. Slide 108: Our portfolio to deliver Precision at Scale

    Slide 108: Our portfolio to deliver Precision at Scale

    INVESTOR DAY 2022 Not for promotional use Our portfolio to deliver Precision at Scale 108 LUNG CANCER PORTFOLIO BLU-222 AREA PDGFRA GIST RET-altered cancers Advanced SM Non-Advanced SM EGFRm NSCLC CDK2 vulnerable breast & other cancers GLOBAL TAMs PRODUCTS ~250,000+ patients 4+ marketed products by

  109. Slide 109: Anticipated near-term milestones

    Slide 109: Anticipated near-term milestones

    INVESTOR DAY 2022 Not for promotional use Anticipated near-term milestones 109 PROGRAMAREA OF FOCUSMILESTONETIMING AYVAKIT Non-Advanced SM Submit sNDAto FDAQ4 2022 Present full registrational data from PIONEER trialQ4 2022 / Q1 2023 BLU-263Report top-line 12-week Part 1 data from HARBOR trialQ4 2022

  110. Slide 110: Precision at Scale: key themes from today's presentation

    Slide 110: Precision at Scale: key themes from today's presentation

    INVESTOR DAY 2022 Not for promotional use 110 Expanding AYVAKIT to treat patients with non-advanced SM to realize a compelling near- term growth opportunity Tackling important medical problems representing significant opportunities in lung, breast and other cancers Building on proven research track

  111. Slide 111: Kate Haviland, Chief Executive Officer

    Slide 111: Kate Haviland, Chief Executive Officer

    KATE HAVILAND Chief Executive Officer

  112. Slide 112: "2027 Blueprint" strategy - double our impact, in half the time

    Slide 112: "2027 Blueprint" strategy - double our impact, in half the time

    INVESTOR DAY 2022 Not for promotional use 112 “2027 Blueprint” strategy -double our impact, in half the time Approved medicines Disease leadership areas Late-stage clinical programs Research platforms Cumulative development candidates 2011-2022 2 1 2 1 14 Planned 2022-2027 4+ 3+ 4+ 2 25+ 2027

  113. Slide 113: Thank you

    Slide 113: Thank you

Source: SEC EDGAR · 8-K filed Nov 1, 2022

More decks from Blueprint Medicines Corp